This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gallwitz, B. Search for Related Content Social Bookmarking                         What's this?

Managing the β-cell with GLP-1 in type 2 diabetes

Department of Medicine IV and the Outpatient Clinics for Endocrinology, Diabetes, and Metabolism, Eberhard-Karls-University of Tübingen, Tübingen, Germany, Baptist.Gallwitz{at}med.uni-tuebingen.de

The clinical course of type 2 diabetes mellitus is characterised by a progressive decline in β -cell mass. The changing β-cell mass reflects a shifting balance between β-cell neogenesis, islet neogenesis and β-cell apoptosis. In persons with diabetes, administration of exogenous glucagon-like peptide-1 (GLP-1) improves glucose sensitivity and insulin synthesis and may help increase β cell mass. As the effects of GLP-1 on the β cell are becoming better understood at both the molecular and cellular levels, it has become possible to develop therapies with the potential to harness and sustain the positive effects of endogenous GLP-1 in patients with type 2 diabetes. Data from in vitro, preclinical and phase II studies show promising results with GLP-1 analogues in improving β-cell function in patients with type 2 diabetes. For example, in vitro models have shown the GLP-1 analogue liraglutide inhibits β-cell apoptosis in isolated neonatal rat islets. In vitro, animal models demonstrate increasing β-cell mass with liraglutide administration. Results from a recently completed phase II clinical trial with liraglutide in patients with type 2 diabetes demonstrate that daily treatment markedly improves β -cell function as shown by an increased first-phase insulin response and secretory capacity and a decreased proinsulin:insulin ratio. Now, phase III trials continue to bear out the potential for liraglutide for treatment of patients with type 2 diabetes. Br J Diabetes Vasc Dis 2008; 8 (Suppl 2): S19-S25

Key Words: apoptosis • β cell • glucagon-like peptide-1 analogues • insulin response • neogenesis

References

• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study Group. Perspectives in diabetes. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.[Abstract]
• Butler AE, Janson J., Bonner-Weir S. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.[Abstract/Free Full Text]
• Cabrera O., Berman DM, Kenyon NS et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006;103:2334-39.[Abstract/Free Full Text]
• Drucker DJ, Philippe J., Majsov S. et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434-38.[Abstract/Free Full Text]
• Drucker DJ The biology of incretin hormones. Cell Metab 2006;3:153-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• rskov C., Holst JJ, Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13.[Abstract/Free Full Text]
• Mojsov S., Weir GC, Habener JF Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-9.[Web of Science][Medline] [Order article via Infotrieve]
• Degn KB, Brock B., Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependant insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403.[Abstract/Free Full Text]
• Nauck MA, Heimesaat MM, Behle K. et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46.[Abstract/Free Full Text]
• de Heer J., Holst JJ Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007;56:438-43.[Abstract/Free Full Text]
• Ling Z., Wu D., Zambre Y. et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 2001;438:382-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bulotta A., Hui H., Anastasi E. et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 2002;29:347-60.[Abstract]
• Farilla L., Bulotta A., Hirshberg B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lugari R., Dell'Anna C., Ugolotti D. et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 2000;32:424-8.[Web of Science][Medline] [Order article via Infotrieve]
• Vilsbøll T., Krarup T., Madsbad S., Holst JJ Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud 2005;2:61-9.[CrossRef][Medline] [Order article via Infotrieve]
• Eng J., Kleinman WA, Singh L. et al. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 1992;267:7402-05.[Abstract/Free Full Text]
• Kolterman OG, Kim DD, Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81.[Abstract/Free Full Text]
• Chen YE, Drucker DJ Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108-15.[Abstract/Free Full Text]
• Byetta [package insert]. San Diego: Amylin Pharmaceuticals Inc, 2007.
• Vilsbøll T., Zdravkovic M., Le-Thi T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.[Free Full Text]
• Madsbad S., Brock B., Perrild J. et al. Fourteen weeks of liraglutide therapy in subjects with type 2 diabetes significantly improves first phase secretion and maximal beta-cell secretory capacity. Diabetologia 2006;49(suppl 1):A004.
• Chang AM, Jakobsen G., Sturis J. et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91.[Abstract/Free Full Text]
• Degn KB, Juhl CB, Sturis J. et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and - and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.[Abstract/Free Full Text]
• Bregenholt S., Moldrup A., Blume N. et al. The GLP-1 analogue, NN2211, inhibits free fatty acid-induced apoptosis in primary rate β -cells. Diabetes 2001;44(suppl 1):A19.
• Bregenholt S., Moldrup A., Knudsen LB, Petersen JS The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rate β-cells. Diabetologia 2001;50(suppl 2):A31.
• Rolin B., Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283: E745-52.[Abstract/Free Full Text]
• Sturis J., Gotfredsen CF, Rømer J. et al. GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br J Pharmacol 2003;140:123-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bregenholt S., Moldrup A., Blume N. et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Comm 2005;330:577-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2 Suppl, S19-S25 (2008)
DOI: 10.1177/1474651408100522


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gallwitz, B. Search for Related Content Social Bookmarking                         What's this?